Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 46

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 46
---
(16) Consists of (i) 22,870 shares of our common stock held by Mr. Jones, (ii) options to purchase 50,000 shares of our common stock held by Mr. Jones that are exercisable within 60 days of March 31, 2025.

(17) Consists of (i) 16,405 shares of our common stock held by Mr. Holstein, and (ii) options to purchase 35,000 shares of our common stock held by Mr. Holstein that are exercisable within 60 days of March 31, 2025.

(18) Consists of (i) 348,900 shares of our common stock, and (ii) options to purchase 749,793 shares of our common stock that are exercisable within 60 days of March 31, 2025.

#### 42Veracyte2025 Proxy Statement
Executive Officers

The names of our executive officers, their ages and their positions as of April 21, 2025 are shown below:

| Name             |     | Age |     | Position                                           |
| Marc Stapley     |     |  55 |     | Chief Executive Officer and Director               |
| Rebecca Chambers |     |  47 |     | Chief Financial Officer                            |
| Phillip Febbo    |     |  58 |     | Chief Scientific Officer and Chief Medical Officer |
| John Leite       |     |  53 |     | Global Chief Commercial Officer                    |
| Annie McGuire    |     |  45 |     | General Counsel and Chief People Officer           |

Executive Officer Information

For information regarding Mr. Stapley, please refer to “Proposal No. 1- Election of Directors.”

| Rebecca Chambershas served as our Chief Financial Officer since July 2021. Prior to her appointment, Ms. Chambers served as Chief Financial Officer of Outset Medical, Inc., a medical technology company, from 2019 to 2021. Prior to that, Ms. Chambers served in a number of roles at Illumina, Inc., a genetic tools company, including as the Vice President, Financial Planning and Analysis from 2017 to 2019, as Vice President, Investor Relations and Treasury from 2015 to 2017, and as Senior Director, Investor Relations from 2012 to 2015. Previously, Ms. Chambers served as Head of Investor Relations and Corporate Communications at Myriad Genetics, Inc., a molecular diagnostic company, from 201